HomeIMCR • NASDAQ
add
Immunocore Holdings PLC - ADR
Previous close
$35.60
Day range
$35.34 - $36.99
Year range
$33.05 - $76.98
Market cap
1.79B USD
Avg Volume
326.38K
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 75.40M | 26.18% |
Operating expense | 38.64M | 10.36% |
Net income | -11.62M | 31.73% |
Net profit margin | -15.41 | 45.87% |
Earnings per share | -0.18 | 37.67% |
EBITDA | -15.02M | -18.05% |
Effective tax rate | -14.67% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 859.60M | 97.59% |
Total assets | 1.02B | 82.87% |
Total liabilities | 664.23M | 220.50% |
Total equity | 359.14M | — |
Shares outstanding | 50.02M | — |
Price to book | 4.96 | — |
Return on assets | -3.97% | — |
Return on capital | -4.81% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -11.62M | 31.73% |
Cash from operations | 23.47M | 52,060.00% |
Cash from investing | -350.33M | -25,013.33% |
Cash from financing | -818.00K | -107.07% |
Net change in cash | -327.84M | -2,507.37% |
Free cash flow | 23.59M | 596.15% |
About
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
Founded
2008
Website
Employees
497